Choose Your Country or Region

Buparlisib (BKM120)

Name: Buparlisib (BKM120)
Brand: Selleck Chemicals
SKU: S2247
Rating: 5 (222 reviews)

Catalog No.S2247 Synonyms: NVP-BKM120

For research use only.

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

CAS No. 944396-07-0

Selleck's Buparlisib (BKM120) has been cited by 222 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	Click to View More Targets
52 nM	116 nM	166 nM	262 nM	2.4 μM	Click to View More Targets

In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. ^[1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. ^[2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. ^[3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

glioma cell lines	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFL5N2E4Omh?		MUnJR\|UxRTFvMt88US=>	M4\rcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
U87	M3TLbWFxd3C2b4Ppd{BCe3OjeR?=	NU\VWXRvOs7:TR?=	NGPaW4Q4Omh?		MXXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?=	M1;R[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
SNU-601	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHyN2lpPzKq	MUXEUXNQ	NUW4elRYUUN3ME2wMlgyPsLzMD6wOlPPxE1?	NVPXNoQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-1	M3mxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIe4Vog4Omh?	NEfDb5pFVVOR	MnPTTWM2OD1zLkC4NuKyOC5yMklOwG0>	MnuzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-668	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\OO\|Jp	M4fYZmROW09?	Mn7ITWM2OD1zLkW3PeKyOC5yN{VOwG0>	NGDH[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
AGS	NFfT[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXq3Nog>	Ml3PSG1UVw>?	MWDJR\|UxRTFwN{G0xtExNjFzN988US=>	M2LGWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-216	MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M37QNlczcA>?	NVu3fJpETE2VTx?=	NF\RfGdKSzVyPUKuOlkzyrFyLkC4Nu69VQ>?	MojwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIrhd4Y4Omh?	NH3lSG1FVVOR	M{S5TWlEPTB;MT6zOVHDuTBwMEmx{txO	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-638	NHP6VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGroemQ4Omh?	MYXEUXNQ	M2XU[2lEPTB;Mj6yPFLDuTBwMEWz{txO	NEH3UFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-16	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfxPGJKPzKq	MmDNSG1UVw>?	MkH1TWM2OD1zLkW3N:KyOC5yMEJOwG0>	NEHwXHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-484	M2O3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mo\NO\|Jp	M4ewbGROW09?	Mn72TWM2OD1zLkeyPOKyOC5yNEZOwG0>	M{HZOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-620	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV63Nog>	MY\EUXNQ	NIHtNnNKSzVyPUKuPVM6yrFyLkCwNe69VQ>?	M3TITlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-719	M{DWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1KyTlczcA>?	MkHkSG1UVw>?	NUHVVoM{UUN3ME2zMlA{P8LzMD6wN\|LPxE1?	NGOxdoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
MM cell lines	M2jKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCxNO69VQ>?	M3zKSlI1cA>?	NEe1c3BFVVOR	M4DpRWlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>?	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MEe0PFUoRjJ{MkC3OFg2RC:jPh?=
ARP-1	NWLJV2pNSXCxcITvd4l{KEG\|c3H5	MVyxNO69VQ>?	MknZNlRp	NHzscYVFVVOR	NWHXNXpzcW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyN{S4OUc,OjJ{MEe0PFU9N2F-
colon cancer cell lines	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrlNE0yOM7:TR?=	NEjmSlE4Omh?	MkjxSG1UVw>?	M3XTNGlEPTB;Md88US=>	NVvCTpNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
gastric cancer cell lines	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPiRW9ZOC1zMN88US=>	NIXRRZU4Omh?	NITrNmFFVVOR	NIrFV2dKSzVyPUKtOe69VQ>?	NHHFbnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
HCT-116/HT-29/MKN-45	NILKZphCeG:ydH;zbZMhSXO\|YYm=	MYSy{txO	MnHaOFhp		M2PZUZNpcW[2IHnuJGczKHCqYYPl	MnuyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
HT-29 and HCT-116	NH7BXW1E[XOyYYPlJIF{e2G7	MnnzOe69VQ>?	MV6yOIg>		NEn0UI5qdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm=	NHLy[oo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
PIK3CA-mutant MCF7	M1LpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TUfmdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P	MnPkO\|Jp		NXvle3VNT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd\|bl2=	NH3CTWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N\|k3Pyd-MkK2OVM6Pjd:L3G+
PIK3CA-mutant MCF7	MkTzT4lv[XOnIFHzd4F6	NFzqV2dKSzVyPUGxOOKyO26P	MU[3Nog>		NFn4XJFKSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz	NVLCVFVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
MCF7-myr-Akt	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;HTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>?	MXq3Nog>		NHTH[IVIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?=	NFv5NJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N\|k3Pyd-MkK2OVM6Pjd:L3G+
Y1 cell line	M{DnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmwMlHPxE1xMd88US=>	NUH0OWJyOjSq	MoHCSG1UVw>?	NU\qXYVlcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO=	M{LQVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkmyPVA1Lz5{Mk[5NlkxPDxxYU6=
human NSCLC	NIOwR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfvNE42NTMQvF2=	M13YcFczcA>?		NFf6TXZKSzVyPUJOwG0>	MnnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN\|k{RC:jPh?=
human NSCLC	Mm\YT4lv[XOnIFHzd4F6	NIi4fHky\|ryP	NWL1S4J2OjSq		MYXpcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62	MkTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN\|k{RC:jPh?=
JVM2	M1vsWWN6fG:2b4jpZ4l1gSCjc4PhfS=>	M3\UZ\|AvOi1{MN88US=>	MmT6O\|Jp	M1PuR2ROW09?	M1zkWWlEPTB;MD65{txO	NIPzfZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
EHEB	Mk\ZR5l1d3SxeHnjbZR6KGG\|c3H5	NUOxOoNPOC5{LUKw{txO	MlfFO\|Jp	NYjqZZU6TE2VTx?=	NFi1[FFKSzVyPUCuO:69VQ>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
MEC2	MnjvR5l1d3SxeHnjbZR6KGG\|c3H5	MofhNE4zNTJyzszN	MmrOO\|Jp	Ml3wSG1UVw>?	NUGwWHBmUUN3ME2wMlfPxE1?	MnzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N\|koRjJ\|MkO4OlM6RC:jPh?=
primary B-CLL lymphocytes	M3zGfmFxd3C2b4Ppd{BCe3OjeR?=	NF\iUWhKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n	NUS1W3VLOjSq	NHTMWoVFVVOR	M2DpO2lEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
primary B-CLL lymphocytes	NX;qeHV[U2mwYYPlJGF{e2G7	MXnJR\|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m	NYn1bZZnOjSq		NVT3eGROcW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
SK-HEP1	NVXOXoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLvNU0zOM7:TR?=	MUC3Nog>	MXHEUXNQ	MX7JR\|Ux97zeMd88US=>	NH\Fdo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3PVE{Pid-MkO0O\|kyOzZ:L3G+
786-0	M4PCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEixSFkyNTJyzszN	NXfNSmp{PzKq	MXPEUXNQ	NVnwWohVUUN3MP-8oFHPxE1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5OUGzOkc,OjN2N{mxN\|Y9N2F-
human HCC cell lines	NEnmPHRE\WyuII\pZYJqdGm2eTDhd5NigQ>?	M{DHd\|AvODB3LUJOwG0>	Mmf6OFhp		NVzCe\|ZpUUN3ME2x{txO	NIfQUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S4PVk6QSd-MkO0PFk6QTl:L3G+
Huh7	NVTJbJUxU2mwYYPlJGF{e2G7	M2Dze\|HPxE1?	MlfzOFhp		NYW0Z3dIe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1	NWHqUlJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFk6QTlpPkKzOFg6QTl7PD;hQi=>
human NSCLC cell lines	NGrpR\|BCeG:ydH;zbZMhSXO\|YYm=	Mo\MNE4yOjVvNN88US=>	NHvzZnEzPGh?	NF;qSYNFVVOR	MUPJR\|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?=	M13od\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[yOFczLz5{M{W2NlQ4OjxxYU6=
Primary CLL cells	M2HwPGFxd3C2b4Ppd{BCe3OjeR?=	M2fVS\|EuOTEQvF2=	M1X6VFQ5cA>?		M32wbYlv\HWlZYOgZZBweHSxc3nzJIlvKEOOTDDj[YxteyCrbnTldIVv\GWwdDDv[kBxem:pbn;zeIlkKG2jcnvldpM>	MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
Primary CLL cells	M2rXc2tqdmG\|ZTDBd5NigQ>?	M{nK[lLPxE1?	M4\pe\|MxdWmw		MU\k[YNz\WG\|ZXSgVGk{UyCjY4Tpeol1gQ>?	MoHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
Primary CLL cells	M3G3WWN6fG:2b4jpZ{BCe3OjeR?=	MWWy{txO	MVqyOIg>		M1jMfIlv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm=	NIWyOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
LC-1/SQSF	NFvnOYlHfW6ldHnvckBCe3OjeR?=	NIm3Spg{\|ryP	M3qxRlI1cA>?	NXXLSG1DTE2VTx?=	Mo\n[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6MEC5N{c,OjN7OECwPVM9N2F-
BCR-ABL	M1vB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTxe\|JEOC5{NT2xNO69VQ>?	NEmyZlU1\A>?		NYfVZohbe2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?=	NXqxclRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQ3OTJpPkK0NlQ1PjF{PD;hQi=>
T-ALL	MVnBdI9xfG:\|aYOgRZN{[Xl?	NXPH[YJl[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l	NI\URpYzPCCxcjC0PIg>	MYXEUXNQ	NUTR[29O[W[oZXP0d{B1cGViUFmzT{Bx[XSqd3H5JIlvKFRvQVzMJINmdGxibHnu[ZM>	M1rHXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{GwO\|M3Lz5{NEOxNFc{PjxxYU6=
H1975	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi2[GkxNjNvOT62{txO	NEXt[pY4Omh?	M3q2emROW09?	M4nkSmlEPTB;MT6zPFXPxE1?	NF3WXXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzO\|g1Pid-MkSzN\|c5PDZ:L3G+
H1975	MoXYRZBweHSxc3nzJGF{e2G7	MkXLNu69VQ>?	NFO0VlczPGh?	MnToSG1UVw>?	M{W3Tolv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6	Mn;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{e4OFYoRjJ2M{O3PFQ3RC:jPh?=
BON	NIG5WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWWxMVXPxE1?	M1KyXVczcA>?		MUPk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	M{DDT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESzOVI{Lz5{NES0N\|UzOzxxYU6=
BON	M4XTN2Fxd3C2b4Ppd{BCe3OjeR?=	MXGxMVXPxE1?	NEnBT2ozPGh?		NHXlZYRqdmO{ZXHz[ZMh[XCxcITvd4l{	NGezRlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0N\|UzOyd-MkS0OFM2OjN:L3G+
GBM	NXP4ZWx3SXCxcITvd4l{KEG\|c3H5	NInFPFYz\|ryP	MYe0PIg>	M{DMZmROW09?	NUjufJpLcW6mdXPl[EBpcWeqZYKgcIV3\Wy\|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyMES5Nkc,OjR3MEC0PVI9N2F-
FaDu	NIXIbpBHfW6ldHnvckBCe3OjeR?=	NULIOnNSPSEQvF2=	M2jlXVI1KGh?	MYjEUXNQ	MoXiVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUG0O{c,OjR4M{GxOFc9N2F-
EMT6	MU\GeY5kfGmxbjDBd5NigQ>?	NXfXNYhrPSEQvF2=	MoSyNlQhcA>?	MVrEUXNQ	MnPNVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	NX\PWFk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|EyPDdpPkK0OlMyOTR5PD;hQi=>
HCT116	Mn3nSpVv[3Srb36gRZN{[Xl?	M2e2O\|Uh\|ryP	MXqyOEBp	MmPISG1UVw>?	MVfS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	M{\rZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
U87	M{SzWmZ2dmO2aX;uJGF{e2G7	MkD4OUDPxE1?	NEHDRZIzPCCq	MoPvSG1UVw>?	MnHEVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
Saos-2	NWfwfFFFTnWwY4Tpc44hSXO\|YYm=	NV\VSHNDPTBizszN	M1[1bFQ5KGh?		M2PQWWlvcGmkaYTzJINmdGxiaX72ZZNqd25?	MoG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63	MVnGeY5kfGmxbjDBd5NigQ>?	NEfBWZc2OCEQvF2=	NWO0PJhqPDhiaB?=		M2PsVmlvcGmkaYTzJINmdGxiaX72ZZNqd25?	NFrsSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	M{Ty[mZ2dmO2aX;uJGF{e2G7	MnTSOVAh\|ryP	NFPFfWg1QCCq		M3;DS2lvcGmkaYTzJINmdGxiaX72ZZNqd25?	NXW0ZXI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
Saos-2	M33sO2Z2dmO2aX;uJGF{e2G7	NVy2N4VqPTBizszN	NXfENJNIPDhiaB?=		Mkn3TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW\|c3nvci=>	MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63	MorpSpVv[3Srb36gRZN{[Xl?	NIjwSXk2OCEQvF2=	MXy0PEBp		MXPJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	Mom3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1	MmrDSpVv[3Srb36gRZN{[Xl?	M2jHT\|UxKM7:TR?=	MkC0OFghcA>?		NV7EbFVCUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	M{Htb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
Saos-2	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\neoE2OCEQvF2=	M4rSVVQ5KGh?		MmP1TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
MG-63	NHvhT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ruZ\|UxKM7:TR?=	M4\xXVQ5KGh?		NYf3bnRmUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
SJSA-1	M2\DfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfpdpE2OCEQvF2=	NHjJPJY1QCCq		NUjQXJVCUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	M4XoWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
LN18	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jwXVIxKM7:TR?=	NYfOOm5NPzJiaB?=	M4\tVWROW09?	M2\VcmlEPTB:NTFOwG0>	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LN229	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW3RowzOCEQvF2=	NX:2U2xzPzJiaB?=	M3\ZNmROW09?	Mm\PTWM2ODx3IN88US=>	NIHyUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LNZ308	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorTNlAh\|ryP	MmDFO\|IhcA>?	MkXOSG1UVw>?	NH7OV4tKSzVyPEWg{txO	NGXjXFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
T98G	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LPfVIxKM7:TR?=	MoLlO\|IhcA>?	NHrwW\|ZFVVOR	NWq4U2NvUUN3MEy1JO69VQ>?	NEHpVmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
U87	M{PudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TGcVIxKM7:TR?=	NIPUTmI4OiCq	NXLVfplxTE2VTx?=	NYHTUJFJUUN3MEy1JO69VQ>?	NGXiNnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN18	MkD6SpVv[3Srb36gRZN{[Xl?	NUHyNWl7PSEQvF2=	NYfycWxLOjRiaB?=	M3vUR2ROW09?	NUPWU\|JuUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?=	NGDZXHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LNZ308	NUDPS25uTnWwY4Tpc44hSXO\|YYm=	MYq1JO69VQ>?	NGjvOHgzPCCq	MnK0SG1UVw>?	M3ewfWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	NYLlb4k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
MDA-MB-175	M2XpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xJO69VQ>?	MlTIOUBl	MnvxSG1UVw>?	M3\GbGlEPTB:MTFOwG0>	NFv6R4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-134	NYL4ZlU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTjOpQyKM7:TR?=	NEWzUXI2KGR?	NVnJWJBOTE2VTx?=	Ml[2TWM2ODxzIN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1500	NFL1cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC3NUDPxE1?	M4PPe\|Uh\A>?	MUPEUXNQ	NGrzVWVKSzVyPEGg{txO	M1q0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
EFM-19	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3UNUDPxE1?	MVi1JIQ>	MnP6SG1UVw>?	NWOydnRyUUN3MEyxJO69VQ>?	NUSwPIluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
ZR-75-30	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWOxJO69VQ>?	MV21JIQ>	M17TWGROW09?	Ml\vTWM2ODxzIN88US=>	MojYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-361	M2HuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rONFEh\|ryP	M4P6flUh\A>?	M{S2fmROW09?	MoDxTWM2ODxzIN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
T-47D	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDYTFYyKM7:TR?=	M3\DV\|Uh\A>?	M2X1XGROW09?	MXrJR\|UxRDFizszN	MmjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
SK-BR-3	NYnjcXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjadowyKM7:TR?=	M4i4VVUh\A>?	NYnPS3hCTE2VTx?=	M1XJNWlEPTB:MTFOwG0>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
UACC-732	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnlbWZjOSEQvF2=	M{PWcFUh\A>?	NYjocZRETE2VTx?=	NY\BRnQ4UUN3MEyxJO69VQ>?	NXS3dIw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-474	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXMNUDPxE1?	MX[1JIQ>	NVrQboNSTE2VTx?=	NVHWWnZwUUN3MEyxJO69VQ>?	MnvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC202	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWixJO69VQ>?	NUj6OIFOPSCm	MkTRSG1UVw>?	NFTzXJlKSzVyPEGg{txO	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MCF7	NYnBUFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnONUDPxE1?	NXG1ZmQ6PSCm	NF;sUoRFVVOR	M4m3dWlEPTB:MTFOwG0>	MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-415	NXPIZ3hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PQdlEh\|ryP	NHPDW5k2KGR?	NWD2R5E4TE2VTx?=	M1mydGlEPTB:MTFOwG0>	M13wd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-453	NX7JPXFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxJO69VQ>?	MYW1JIQ>	NULMbnVGTE2VTx?=	MkPaTWM2ODxzIN88US=>	MorRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
ZR-75-1	M4rwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\4fVEh\|ryP	MX[1JIQ>	NGnqN2xFVVOR	NEPmWY1KSzVyPEGg{txO	M{L2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC38	NGjiRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDIe3RrOSEQvF2=	NYjlRlBoPSCm	Ml:xSG1UVw>?	MmnOTWM2ODxzIN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1419	NEnZe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rjUVEh\|ryP	NXnkdXZ1PSCm	NE\Fco5FVVOR	MVXJR\|UxRDFizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
UACC-812	M3mzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILEOY4yKM7:TR?=	MYq1JIQ>	M3z0NGROW09?	NU\nb5Q6UUN3MEyxJO69VQ>?	MkXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1187	M4rvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\oNUDPxE1?	Ml;POUBl	M3v4dWROW09?	M1W3SmlEPTB:MTFOwG0>	MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
KPL-1	M3;UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX6xJO69VQ>?	MnP5OUBl	NUHxUIxLTE2VTx?=	Mn3nTWM2ODxzIN88US=>	M2r5T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
SUM-225	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmxJO69VQ>?	Ml\pOUBl	NV3KXZprTE2VTx?=	NWXneGJKUUN3MEyxJO69VQ>?	NGXMc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
EFM-192A	NFWycnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPuVJFlOSEQvF2=	MYK1JIQ>	NX;OU2pCTE2VTx?=	NXnQSnVyUUN3MEyxJO69VQ>?	NHTxSnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
JIMT-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzuOXYyKM7:TR?=	NXXqOXNqPSCm	NFrUbWhFVVOR	NXWxepZVUUN3MEyxJO69VQ>?	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1143	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\xNUDPxE1?	MXq1JIQ>	NFXKVnVFVVOR	MWjJR\|UxRDFizszN	NXO3UmhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC2218	NHXxZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDLU2MyKM7:TR?=	NFnRUY82KGR?	MUjEUXNQ	NUDIcFY5UUN3MEyxJO69VQ>?	Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-468	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTVNUDPxE1?	MWO1JIQ>	MYrEUXNQ	M3vhe2lEPTB:MTFOwG0>	M1K5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
BT-20	NUW5blM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP2UFA{OSEQvF2=	NGXCXnA2KGR?	NHHMR2NFVVOR	M3\KSGlEPTB:MTFOwG0>	NEDaOGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-435	M3vTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfwWWVOOSEQvF2=	NInzenI2KGR?	MUXEUXNQ	NGW2SVlKSzVyPEGg{txO	NFjiUIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
BT-549	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnDNUDPxE1?	NV7SfnNOPSCm	NYT0XYtTTE2VTx?=	MV;JR\|UxRDFizszN	NV63cYhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1806	NWLRcpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH1NUDPxE1?	NELM[3E2KGR?	M1\0U2ROW09?	NGfzWYhKSzVyPEGg{txO	NIrOR4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1937	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SyVlEh\|ryP	NWHkR3pvPSCm	Mlq2SG1UVw>?	MljiTWM2ODxzIN88US=>	M4\nXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
Hs578T	M4nOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzBSIwyKM7:TR?=	NF\tR3Q2KGR?	MUDEUXNQ	NVLi[nBtUUN3MEyxJO69VQ>?	M3PEcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MCF7	M{XpW2N6fG:2b4jpZ{BCe3OjeR?=		NFXVWmg4OiCq	NXfsbJFHTE2VTx?=	MnPoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
DU145	MV;DfZRwfG:6aXOgRZN{[Xl?		M{Tzb\|czKGh?	NUfwTnN4TE2VTx?=	MlfIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N\|Uh\|ryP	MknwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	MnrjR5l1d3SxeHnjJGF{e2G7		MnrPO\|IhcA>?	M{ezWmROW09?	MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N\|Uh\|ryP	MojVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
U87MG	NVGzPGxiS3m2b4TvfIlkKEG\|c3H5		MmDmO\|IhcA>?	NUD4Rm11TE2VTx?=	M2DmOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2=	MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	NEfydlBHfW6ldHnvckBCe3OjeR?=		MnXmNUBp	NYTJU2Y3TE2VTx?=	MlrZTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1?	MoPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
DU145	M{CyemZ2dmO2aX;uJGF{e2G7		M3\0bFEhcA>?	MkDjSG1UVw>?	M4qwdGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO\|Mh\|ryP	MonrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	MVfGeY5kfGmxbjDBd5NigQ>?		NVLGOmdNOSCq	MYXEUXNQ	M1jaeWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	M3Lod\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
MCF7	NIjZ[3BHfW6ldHnvckBCe3OjeR?=		MkjINUBp	MX3EUXNQ	NYjZ[ZN7UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgSVU1PUtibYX0ZY51NW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlEh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
U87MG	NFyxbXRHfW6ldHnvckBCe3OjeR?=		MkHyNUBp	NXz1NpRtTE2VTx?=	M3y0e2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
A2780	NV;zb2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV7pUZMyPzJiaB?=	M{fkcGROW09?	MWXFR\|UxRTBwNUKg{txO	NUOxeoFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7	NXHlSXBoTnWwY4Tpc44hSXO\|YYm=	NV\JcopMOSEQvF2=	NYnKdFdsOSCq	NWXTWZN3TE2VTx?=	MYPJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>?	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMES0NFMoRjJ3MEC0OFA{RC:jPh?=
BNL	NGTlVplHfW6ldHnvckBCe3OjeR?=	NF;LTYoyKM7:TR?=	MX2xJIg>	M4GxTGROW09?	MoW5TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNESwN{c,OjVyMES0NFM9N2F-
BON-1	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;2OZZnPTByIH7N	MUCxNEBl	M{LnR2ROW09?	M{LUfWlvcGmkaYTzJINmdGxiZ4Lve5Rp	M{PkdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
BON-1	NV3DN4VxTnWwY4Tpc44hSXO\|YYm=	NWnPdVVHPTByIH7N	Mn3wOEBp	MWTEUXNQ	NGT2[2JKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{NkK5Nkc,OjVyMk[yPVI9N2F-
QGP-1	NWi4TFl3TnWwY4Tpc44hSXO\|YYm=	M363UFUxOCCwTR?=	NVLXNXhvPCCq	MmDJSG1UVw>?	NH;5NWNKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	M2jMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
HCT-15	MX\BdI91d3OrczDBd5NigQ>?	NVLWNFN1OTBizszN	MmGyOFghcA>?	NUjlcWN7TE2VTx?=	MXLJcoR2[2W\|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>?	NYjwNpJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
HCT-116	NV[0NHNKSXCxdH;zbZMhSXO\|YYm=	NG\WVFMyOCEQvF2=	M{LzfFQ5KGh?	M1nxdmROW09?	NFznU3RKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36=	M3XxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
NCI-H460	NELh[HpCeG:2b4Ppd{BCe3OjeR?=	MnLpNVAh\|ryP	MkHvOFghcA>?	NH\QTVNFVVOR	NHHnXXVKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	NHTwOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
SKOV-3	MXTBdI91d3OrczDBd5NigQ>?	MkXDNVAh\|ryP	NIfLbnA1QCCq	M{f1S2ROW09?	M2HSO2lv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	M2nCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
BSY-1	NH\ne2tCeG:2b4Ppd{BCe3OjeR?=	MoSzNVAh\|ryP	Mk\hOFghcA>?	NHnuSYNFVVOR	MXLJcoR2[2W\|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	M17VZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-1	MmHBRZBwfG:\|aYOgRZN{[Xl?	M1jXcVExKM7:TR?=	MXe0PEBp	M1;IZmROW09?	NHj3[otKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NVH3dHpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
NCI-H522	MW\BdI91d3OrczDBd5NigQ>?	NXXDcJBZOTBizszN	NHfpSZc1QCCq	NVf1TXpwTE2VTx?=	MVHJcoR2[2W\|IHHwc5B1d3Orcx?=	M1KzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
OVCAR-3	MVHBdI91d3OrczDBd5NigQ>?	Mm\jNVAh\|ryP	M4HQNFQ5KGh?	NWTlZZlkTE2VTx?=	MmO2TY5lfWOnczDhdI9xfG:\|aYO=	Ml7JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
HBC-5	NGjkdYNCeG:2b4Ppd{BCe3OjeR?=	MUCxNEDPxE1?	MnG0OFghcA>?	MojmSG1UVw>?	M4C5cmlv\HWlZYOgZZBweHSxc3nz	NF;xcHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
RXF-631L	MYnBdI91d3OrczDBd5NigQ>?	M{\EOVExKM7:TR?=	MX20PEBp	MnfCSG1UVw>?	MVPJcoR2[2W\|IHHwc5B1d3Orcx?=	M3rGPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-45	MYjBdI91d3OrczDBd5NigQ>?	MVqxNEDPxE1?	MV[0PEBp	NWnaWmN1TE2VTx?=	M1:0RWlv\HWlZYOgZZBweHSxc3nz	M2jp[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
LNCaP	Ml35SpVv[3Srb36gRZN{[Xl?	M2e0RVEh\|ryP			NYnQeYsyW3WycILld5NmeyCyLVHLWEBt\X[nbIO=	M3PIO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO\|k6Lz5{NUO2NFc6QTxxYU6=
LNCaP95	NWCyfXdRTnWwY4Tpc44hSXO\|YYm=	MWOxJO69VQ>?			MYTTeZBxemW\|c3XzJJAuSUuWIHzleoVtew>?	MmjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NkC3PVkoRjJ3M{[wO\|k6RC:jPh?=
A549	MljzSpVv[3Srb36gRZN{[Xl?	NHvLd442ODBibl2=	NV;wPFljPDhiaB?=	NF65[mJFVVOR	M3fre2lvcGmkaYTzJGFsfCCjY4TpeoF1cW:w	M3KzVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO\|I6QTxxYU6=
A549	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHqS21SOSEQvF2=	MoHPO\|IhcA>?	M{fhU2ROW09?	NVruUlExUW6qaXLpeJMh[2WubDDndo94fGh?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|N{K5PUc,OjV7M{eyPVk9N2F-
H522	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf0S\|JrOSEQvF2=	MoXPO\|IhcA>?	NF65fIpFVVOR	MYXJcohq[mm2czDj[YxtKGe{b4f0bC=>	NGXYVmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzO\|I6QSd-MkW5N\|czQTl:L3G+
SKMES-1	MVfDfZRwfG:6aXOgRZN{[Xl?	NXHDT4duOSEQvF2=	NG\YNGc4OiCq		M2myPGlv\HWlZYOgZ4VtdCCmZXH0bC=>	MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
H596	NHXzTmNHfW6ldHnvckBCe3OjeR?=	M3Xz[FEh\|ryP			NGLDZmpKdXCjaYLzJINmdGxibXnndoF1cW:w	NXWyS4VDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCC2450	NWXSbG1oTnWwY4Tpc44hSXO\|YYm=	M3jUXFEh\|ryP			MoDYTY1x[Wm{czDj[YxtKGmwdnHzbY9v	NVfsN2pyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCT116	MkKxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH[4cnM4OiCqcoO=		NWDBTXpPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvPDhizszNMi=>	NHrhSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
MCF7	M3y3cGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MljuO\|IhcHK\|		MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFizszNMi=>	NGH0T5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
U87MG	M{SzWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmTrO\|IhcHK\|		MoLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOEfNS{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT62OEDPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
A549	NIjCOlZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVzESpM1PzJiaILz		NGS0UJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFch\|ryPLh?=	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
HeLa	Ml[xRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmLJO\|IhcHK\|		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{Sg{txONg>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
HCT116	NVSxZ4R3TnWwY4Tpc44h[XO\|YYm=	NVXFcXhLOTBidV2=	NYS5dHFOOSCqch?=		Mme3TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhSWu2IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm\|aYO=	NX[4VZhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O\|Y2QTB7PD;hQi=>
A2058 melanoma	MXfD[YxtKGO7Y3zlJIF{e2G7	MVy1JJVO	NV3SbFdYOjRiaILz		MVLD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDBNlA2QCCvZXzhco9u[SClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhW3WkR{GgdIhie2ViYYSgOUB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{	NGLtc249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyPVU6Oid-Mki4Nlk2QTJ:L3G+
A2058 melanoma	MX;D[YxtKGO7Y3zlJIF{e2G7	NGGwWJc2KHWP	M2C0OlI1KGi{cx?=		MX;D[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDBNlA2QCCvZXzhco9u[SClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDC1JJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5Nkc,Ojh6Mkm1PVI9N2F-
SKOV3	NULlO\|g2S2WubDDjfYNt\SCjc4PhfS=>	NH;DeIQzKHWP	NGfuU4MzPCCqcoO=		NXPac\|F6S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhOiC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m\|	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
SKOV3	MoLaR4VtdCCleXPs[UBie3OjeR?=	NGKzVo8zKHWP	NXW4cnY3OjRiaILz		MlXOR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gV2tQXjNiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KFO3YlexJJBp[XOnIHH0JFIhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	NYGze3l3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
MDA-MB-231	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		M2HXTlczKGi{cx?=		M2DjcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPFgh\|ryPLh?=	M3nuVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
PC3	M{XjTGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYrhe3FkPzJiaILz		MnjvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1MlM1KM7:TT6=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
T47D	NILRbFdEgXSxdH;4bYNqfHliYYPzZZk>		NEfydZM4OiCqcoO=		MnvuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOk46OiEQvF2u	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
MCF7	M4HhWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHK2WXY4OiCqcoO=		NXjPZW1wS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTFwMEWg{txONg>?	NF70UXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO\|QzQSd-MkmxNFc1Ojl:L3G+
TC32	NXi4dY13eUiWUzDhd5NigQ>?				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	M4XyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	M1K4epFJXFNiYYPzZZk>				NGTq[\|RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MYrxTHRUKGG\|c3H5				MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NXrmNlFQeUiWUzDhd5NigQ>?				NGPmVo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MkSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M{nOfpFJXFNiYYPzZZk>				MnjWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	Mo[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M4S1RpFJXFNiYYPzZZk>				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MnTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M3i4VpFJXFNiYYPzZZk>				M2i4b5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M1zWe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M1TWfpFJXFNiYYPzZZk>				M2LwWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MoHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MnjldWhVWyCjc4PhfS=>				MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	MkLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NWXOdXh6eUiWUzDhd5NigQ>?				NEH4empyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MonrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NHy2fYpyUFSVIHHzd4F6				NEjzRWJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M1LkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	M4TiTJFJXFNiYYPzZZk>				MlqydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	M3rwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M{jHO5FJXFNiYYPzZZk>				NFTMdmxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	M3\wdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	M3XwVZFJXFNiYYPzZZk>				NH\ZZ\|VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	MojzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NFvQOW1yUFSVIHHzd4F6				MonBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	Ml24QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MlnldWhVWyCjc4PhfS=>				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	NEfqR249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	M{KxNZFJXFNiYYPzZZk>				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	Mn64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	M2\BNZFJXFNiYYPzZZk>				NHvVNmtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	NY\YdnlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NXjrN\|UxeUiWUzDhd5NigQ>?				MlfWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	MnrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NXq4OZFFeUiWUzDhd5NigQ>?				NF3q[HNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	NETLV5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NYX5ZnJbeUiWUzDhd5NigQ>?				MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NXzWXY5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M4jxZZFJXFNiYYPzZZk>				NVe2bGtveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	M3jOTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M37XVJFJXFNiYYPzZZk>				NFnoZ3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NInLVJhyUFSVIHHzd4F6				NXz5d\|BpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MoLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M4PpPZFJXFNiYYPzZZk>				M2XvfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MVrxTHRUKGG\|c3H5				M1W2cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	MmTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MkHMdWhVWyCjc4PhfS=>				M{TG[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MkCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
insect	MWfGeY5kfGmxbjDhd5NigQ>?				MlPWTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKaYOteIFo\2WmIIC4OYFteGijL4CxNVBidHCqYTDFOVQ2UyCvdYThcpQh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODFzIN88UU4>	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
insect	M1TJSWZ2dmO2aX;uJIF{e2G7				MVjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEircz30ZYdo\WRicEi1ZYxxcGFxcEGxNIFteGijIFW1OFJMKG23dHHueEBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xOjlizszNMi=>	NE\CN4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
Sf21	NG\Mc2pHfW6ldHnvckBie3OjeR?=		M{S0clEhcHJ?		MWLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHytcIVv\3SqIF6teIVzdWmwYXygTIl{Pi22YXfn[YQheDFzMHTlcJRiN3KnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJIlve2WldDDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFHs[ZhiPjN\|IGTyZYNmei2kYYPl[EBndHWxcnXzZ4Vv[2VicH;sZZItKEmFNUCgQUAxNjF{NTFOwG0v	NGHsU\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
MCF7	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MofDO\|IhcHK\|		NWHQPVJpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIhiemKxcnnu[{BRUUt\|Q1GgSVU1PUtibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJyNjFOwG0v	NUDa[4hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21	MWnGeY5kfGmxbjDhd5NigQ>?		NIfnNmsyKGi{		MVrJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHytcIVv\3SqIF6teIVzdWmwYXygTIl{Pi22YXfn[YQheDFzMHLleIEwemWlb33ibY5idnRiaIXtZY4h\nWubDDs[Y5ofGhicEi1ZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgbY5{\WO2IHPlcIx{KHW\|aX7nJHBKWDJiYYOgd5Vje3S{YYTlJI1m[XO3cnXkJIFnfGW{IEGgbJIh[nliQXzlfIE3OzNiVILhZ4VzNWKjc3XkJIZtfW:{ZYPj[Y5k\SCyb3zhdoktKEmFNUCgQUAxNjJ\|NDFOwG0v	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
T47D	NH;HflRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXTydHRiPzJiaILz		MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR2N1SgZ4VtdHNiaHHyZo9zcW6pIGDJN2tESSCKMUC0O3IhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlI5PiEQvF2u	NEDK[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
PC3	NYrpZnNWTnWwY4Tpc44h[XO\|YYm=		M4DJNlIhcHK\|		MoXHTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYK0O\|MhdWWjc4Xy[YQh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4{PjVizszNMi=>	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
HT-29	Mlm2R4VtdCCleXPs[UBie3OjeR?=	NGTidFgxNjFzMTD0c{A{KHWP	MkjwNlQhcHK\|		NEHiXY1E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEAxNjFzMTD0c{A{KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7	NYDqbJV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
A2058	NIPyV4FHfW6ldHnvckBie3OjeR?=		M{LBclEhcHJ?		NFHlPGRKdmirYnn0bY9vKG:oIGTPVmMzKGmwIHj1cYFvKEF{MEW4JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFCNQj;Bb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPDF4IN88UU4>	M1G0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=
A2058	NWPuUpBlTnWwY4Tpc44h[XO\|YYm=		MlTwNUBpeg>?		MYnJcohq[mm2aX;uJI9nKFSRUlOxJIlvKGi3bXHuJGEzODV6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJHM3KHCqb4PwbI9zgWyjdHnvckBifCCVZYKyN\|UwOjN4IHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD61OVMh\|ryPLh?=	M{jKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-AKT (T308) / p-AKT (S473) / AKT ; p-FOXO3a (S253) / FOXO3a ; Nuclear NF-κB p65 / NF-κB p65 ; p-ERK / ERK / LC3 ; p-STAT3 / STAT3 / p-ERK / ERK / p-S6 ; p-MET / MET	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a	28036259
Growth inhibition assay	Cell viability	26673665

In vivo

BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. ^[1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. ^[2]

Protocol (from reference)

Kinase Assay:^[1]	PI3K biochemical assay (ATP depletion assay): BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:^[1]	Cell lines: A2780 cells. Concentrations: 0-6.6 μM Incubation Time: 3 days. Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 10³ cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
Animal Research:^[1]	Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice. Dosages: ~60 mg/kg. Administration: Dosed orally daily (q.d.).

References

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

+ Expand

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300	15mg/mL

Chemical Information

Molecular Weight	410.39
Formula	C₁₈H₂₁F₃N₆O₂
CAS No.	944396-07-0
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

Download Buparlisib (BKM120) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	December 12 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):